Curocell
Daejeon
About Curocell
Curocell’s OVIS™ technology enhances immune cells to overcome immune suppression in tumor microenvironments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $67.2M
- Last round: Series Unknown (Jan 2022)
- Website: curocellbtx.com
Industries & Categories
Biopharma, Biotechnology
Canonical: https://fsome.com/organization/curocell-53647 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.